S C Buckingham1, A J Bush, J P Devincenzo. 1. Department of Pediatrics, University of Tennessee, Memphis and LeBonheur Children's Medical Center, 38103, USA.
Abstract
OBJECTIVE: To evaluate the relationship between nasal quantity of respiratory syncytial virus (RSV) and disease severity in hospitalized infants without underlying cardiopulmonary disease or immunodeficiency. METHODS: Nasal aspirates were obtained from hospitalized infants <24 months of age with recently identified RSV infection and evaluated for RSV quantity by a standard plaque assay on HEp-2 cell monolayers. Subjects were classified as having "severe" disease if they required mechanical ventilation at the time of sample collection and as having "nonsevere" disease if they did not. Linear modeling was used to determine the relationship between nasal RSV quantity and various independent variables, including disease severity. RESULTS: Nasal aspirates from 39 patients were evaluated. Age, gender and mean duration of time from symptom onset to sample acquisition (5 days) were similar between the severe (n = 15) and nonsevere (n = 24) groups. Significantly more infants were born at <35 weeks gestation in the severe disease group (7 of 15 vs. 3 of 24, P = 0.017), and infants born at <35 weeks gestation were significantly more likely to be of non-Caucasian ethnicity than were infants born at > or =35 weeks gestation (8 of 10 vs. 12 of 29, P = 0.035). The linear model found that higher nasal RSV quantities were associated with severe disease [mean +/- SEM, 5.06 +/- 0.34 log plaque-forming units (pfu)/ml vs. 3.91 +/- 0.35 log pfu/ml, P = 0.022], gestational age > or =35 weeks (5.44 +/- 0.27 log pfu/ml vs. 3.52 +/- 0.45 log pfu/ml, P = 0.002) and non-Caucasian ethnicity (5.16 +/- 0.30 log pfu/ml vs. 3.80 +/- 0.37 log pfu/ml, P = 0.006). CONCLUSIONS: Nasal RSV quantity correlates with disease severity in hospitalized infants with recently identified RSV infection.
OBJECTIVE: To evaluate the relationship between nasal quantity of respiratory syncytial virus (RSV) and disease severity in hospitalized infants without underlying cardiopulmonary disease or immunodeficiency. METHODS: Nasal aspirates were obtained from hospitalized infants <24 months of age with recently identified RSV infection and evaluated for RSV quantity by a standard plaque assay on HEp-2 cell monolayers. Subjects were classified as having "severe" disease if they required mechanical ventilation at the time of sample collection and as having "nonsevere" disease if they did not. Linear modeling was used to determine the relationship between nasal RSV quantity and various independent variables, including disease severity. RESULTS: Nasal aspirates from 39 patients were evaluated. Age, gender and mean duration of time from symptom onset to sample acquisition (5 days) were similar between the severe (n = 15) and nonsevere (n = 24) groups. Significantly more infants were born at <35 weeks gestation in the severe disease group (7 of 15 vs. 3 of 24, P = 0.017), and infants born at <35 weeks gestation were significantly more likely to be of non-Caucasian ethnicity than were infants born at > or =35 weeks gestation (8 of 10 vs. 12 of 29, P = 0.035). The linear model found that higher nasal RSV quantities were associated with severe disease [mean +/- SEM, 5.06 +/- 0.34 log plaque-forming units (pfu)/ml vs. 3.91 +/- 0.35 log pfu/ml, P = 0.022], gestational age > or =35 weeks (5.44 +/- 0.27 log pfu/ml vs. 3.52 +/- 0.45 log pfu/ml, P = 0.002) and non-Caucasian ethnicity (5.16 +/- 0.30 log pfu/ml vs. 3.80 +/- 0.37 log pfu/ml, P = 0.006). CONCLUSIONS: Nasal RSV quantity correlates with disease severity in hospitalized infants with recently identified RSV infection.
Authors: Varvara Probst; Emily K Datyner; Zaid Haddadin; Danielle A Rankin; Lubna Hamdan; Herdi K Rahman; Andrew Spieker; Laura S Stewart; Claudia Guevara; Erin Yepsen; Jonathan E Schmitz; Natasha B Halasa Journal: J Clin Virol Date: 2020-12-11 Impact factor: 3.168
Authors: John P DeVincenzo; Tom Wilkinson; Akshay Vaishnaw; Jeff Cehelsky; Rachel Meyers; Saraswathy Nochur; Lisa Harrison; Patricia Meeking; Alex Mann; Elizabeth Moane; John Oxford; Rajat Pareek; Ryves Moore; Ed Walsh; Robert Studholme; Preston Dorsett; Rene Alvarez; Robert Lambkin-Williams Journal: Am J Respir Crit Care Med Date: 2010-07-09 Impact factor: 21.405
Authors: Christy M Tabarani; Cynthia A Bonville; Manika Suryadevara; Patrick Branigan; Dongliang Wang; Danning Huang; Helene F Rosenberg; Joseph B Domachowske Journal: Pediatr Infect Dis J Date: 2013-12 Impact factor: 2.129
Authors: Asunción Mejías; Susana Chávez-Bueno; Ana María Ríos; Mónica Fonseca Aten; Brett Raynor; Estrella Peromingo; Perla Soni; Kurt D Olsen; Peter A Kiener; Ana María Gómez; Hasan S Jafri; Octavio Ramilo Journal: Antimicrob Agents Chemother Date: 2005-11 Impact factor: 5.191
Authors: John DeVincenzo; Robert Lambkin-Williams; Tom Wilkinson; Jeffrey Cehelsky; Sara Nochur; Edward Walsh; Rachel Meyers; Jared Gollob; Akshay Vaishnaw Journal: Proc Natl Acad Sci U S A Date: 2010-04-26 Impact factor: 11.205
Authors: D Roumanes; A R Falsey; S Quataert; S Secor-Socha; F E-H Lee; H Yang; S Bandyopadhyay; J Holden-Wiltse; D J Topham; E E Walsh Journal: J Infect Dis Date: 2018-07-02 Impact factor: 5.226
Authors: Monica E Brint; Joshua M Hughes; Aditya Shah; Chelsea R Miller; Lisa G Harrison; Elizabeth A Meals; Jacqueline Blanch; Charlotte R Thompson; Stephania A Cormier; John P DeVincenzo Journal: Pediatr Res Date: 2017-08-09 Impact factor: 3.756
Authors: Edward E Walsh; Lu Wang; Ann R Falsey; Xing Qiu; Anthony Corbett; Jeanne Holden-Wiltse; Thomas J Mariani; David J Topham; Mary T Caserta Journal: J Infect Dis Date: 2018-06-20 Impact factor: 5.226